Kairos Pharma CEO to Present Corporate Strategy at Lytham Partners Healthcare Summit
Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming Lytham Partners Investor Healthcare Summit, scheduled for January 13, 2025. The company’s leadership, including CEO John S. Yu, M.D., and Chief Scientific Officer Neil Bhowmick, will deliver a corporate overview during a virtual presentation at 2:00 PM ET.
The management team will be available for one-on-one virtual meetings throughout the event. Interested parties can arrange meetings through Lytham Partners or register directly via the event website. The presentation will be accessible through a webcast, with replay options available after the event.
Kairos Pharma (NYSE American: KAPA) ha annunciato la sua partecipazione al prossimo Lytham Partners Investor Healthcare Summit, previsto per il 13 gennaio 2025. La leadership dell’azienda, inclusi il CEO John S. Yu, M.D., e il Chief Scientific Officer Neil Bhowmick, presenterà una panoramica aziendale durante una presentazione virtuale alle 14:00 ET.
Il team di gestione sarà disponibile per incontri virtuali individuali durante l’evento. Le parti interessate possono organizzare incontri tramite Lytham Partners o registrarsi direttamente tramite il sito web dell’evento. La presentazione sarà accessibile tramite webcast, con opzioni di replay disponibili dopo l’evento.
Kairos Pharma (NYSE American: KAPA) ha anunciado su participación en la próxima Lytham Partners Investor Healthcare Summit, programada para el 13 de enero de 2025. La dirección de la empresa, incluido el CEO John S. Yu, M.D., y el Chief Scientific Officer Neil Bhowmick, ofrecerán una visión general corporativa durante una presentación virtual a las 2:00 PM ET.
El equipo de gestión estará disponible para reuniones virtuales individuales a lo largo del evento. Las partes interesadas pueden organizar reuniones a través de Lytham Partners o registrarse directamente a través del sitio web del evento. La presentación será accesible a través de un webcast, con opciones de repetición disponibles después del evento.
카이로스 제약(Kairos Pharma) (NYSE American: KAPA)는 2025년 1월 13일 예정인 Lytham Partners Investor Healthcare Summit에 참여할 것이라고 발표했습니다. CEO인 John S. Yu, M.D.와 Chief Scientific Officer인 Neil Bhowmick를 포함한 회사의 리더십이 오후 2시(동부 표준시)에 가상 프레젠테이션을 통해 기업 개요를 제공합니다.
경영진 팀은 행사 동안 개별 가상 회의에 참석할 수 있습니다. 관심 있는 분들은 Lytham Partners를 통해 회의를 조율하거나 행사 웹사이트를 통해 직접 등록할 수 있습니다. 프레젠테이션은 웹캐스트를 통해 시청 가능하며, 행사 후 재시청 옵션이 제공됩니다.
Kairos Pharma (NYSE American: KAPA) a annoncé sa participation au prochain Lytham Partners Investor Healthcare Summit, prévu pour le 13 janvier 2025. La direction de la société, y compris le PDG John S. Yu, M.D. et le directeur scientifique Neil Bhowmick, présentera un aperçu de l’entreprise lors d’une présentation virtuelle à 14h00 ET.
L’équipe de direction sera disponible pour des réunions virtuelles individuelles tout au long de l’événement. Les parties intéressées peuvent organiser des réunions via Lytham Partners ou s’inscrire directement via le site web de l’événement. La présentation sera accessible via un webcast, avec des options de rediffusion disponibles après l’événement.
Kairos Pharma (NYSE American: KAPA) hat seine Teilnahme am bevorstehenden Lytham Partners Investor Healthcare Summit, der für den 13. Januar 2025 geplant ist, angekündigt. Die Unternehmensführung, einschließlich CEO John S. Yu, M.D., und Chief Scientific Officer Neil Bhowmick, wird während einer virtuellen Präsentation um 14:00 Uhr ET einen Unternehmensüberblick geben.
Das Managementteam wird während der Veranstaltung für eintägige virtuelle Meetings zur Verfügung stehen. Interessierte Parteien können über Lytham Partners Meetings arrangieren oder sich direkt über die Veranstaltungswebsite registrieren. Die Präsentation wird über einen Webcast zugänglich sein, mit Replay-Optionen, die nach der Veranstaltung verfügbar sind.
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, and Neil Bhowmick, Chief Scientific Officer, will present a corporate overview at the Lytham Partners Investor Healthcare Summit. The conference is being held virtually on January 13, 2025.
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners or register for the event at
The webcast will also be available for replay following the event.
About Kairos Pharma Ltd.
Based in
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by
View source version on businesswire.com:
CORE IR
Louie Toma
[email protected]
Source: Kairos Pharma, Ltd
FAQ
When is Kairos Pharma (KAPA) presenting at the Lytham Partners Healthcare Summit?
Kairos Pharma (KAPA) is presenting at the Lytham Partners Healthcare Summit on Monday, January 13, 2025, at 2:00 PM ET.
How can investors attend KAPA’s presentation at the Lytham Partners Summit?
Investors can attend virtually by accessing the webcast through kapa or register for one-on-one meetings through Lytham Partners.
Who will be presenting for KAPA at the Lytham Partners Healthcare Summit?
CEO John S. Yu, M.D., and Chief Scientific Officer Neil Bhowmick will present the corporate overview at the summit.
Will KAPA’s Lytham Partners presentation be available for replay?
Yes, the webcast presentation will be available for replay following the event.
How can investors schedule one-on-one meetings with KAPA management?
Investors can arrange one-on-one meetings by contacting Lytham Partners directly or by registering at
link
